Levetiracetam
Product Images NDC 68788-7592

8 FDA label images from Preferred Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68788-7592). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' compares the percentage of patients responding to placebo and two doses of Levetiracetam. The chart shows about 7.4% response for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, with the Levetiracetam groups marked as statistically significant versus placebo.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' illustrating the percentage of patients achieving this reduction. It compares placebo with Levetiracetam at 1000 mg/day and 2000 mg/day doses, showing responder rates of 6.3%, 20.8%, and 35.2% respectively. Statistical significance markers indicate that both Levetiracetam doses have a statistically significant higher responder rate compared to placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing the percentage of patients achieving response between placebo and Levetiracetam 3000 mg/day. The placebo group (N=104) shows a 14.4% responder rate, while the Levetiracetam group (N=180) shows a 39.4% responder rate, marked as statistically significant versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' showing the percentage of patients responding to treatment. The chart compares placebo (N=97) with a responder rate of 19.6% to Levetiracetam (N=101) with a responder rate of 44.6%. A note indicates statistical significance versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
Bar chart titled 'Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5' comparing placebo and Levetiracetam. The Y-axis displays percentage of patients, with placebo group showing 19.6% and Levetiracetam group showing 43.1%, indicating a higher responder rate for Levetiracetam. A note indicates statistical significance versus placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' comparing placebo and Levetiracetam. The y-axis shows the percentage of patients, with bars indicating 45.2% response for placebo (N=84) and 72.2% for Levetiracetam (N=79). An asterisk denotes statistical significance versus placebo.*
FDA Label Image

Levetiracetam Tablet Usp 500mg (Levetiracetam Fig7)

Levetiracetam Tablet Usp 500mg (Levetiracetam Fig7)
Levetiracetam Tab USP 500mg packaging label from Preferred Pharmaceuticals, Inc. The label states the product is a generic for Keppra, each film-coated tablet contains levetiracetam 500 mg, and the manufacturer is Aurobindo Pharma Limited. The label includes storage instructions, space for expiration date, lot number, batch number, and insurance product numbers, with directions for use in both English and Spanish printed on a yellow background.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of the active ingredient Levetiracetam, showing its molecular arrangement including a pyrrolidone ring, an amide group, and an ethyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.